Heidi Jacobe will join Duke University School of Medicine as chair of the Department of Dermatology, according to an announcement from the institution.

The appointment places Jacobe at the head of one of the country's leading academic dermatology departments. Duke Dermatology has long been a center for clinical care, research, and training in medical and surgical dermatology, and the chairmanship carries responsibility for the department's clinical, scientific, and educational missions.

For the dermatology community, a departmental chair appointment at an institution of Duke's stature is more than an administrative change. It shapes research priorities, fellowship and residency training, and the clinical programs that patients with complex inflammatory disease, cutaneous malignancy, and rare dermatologic conditions rely on. Who holds the chair determines, in large measure, which questions the department pursues and how it allocates resources across patient care and investigation.

The announcement names Jacobe to the post but does not detail her prior positions, research focus, or the timeline for her transition to Duke. Readers of Derm Field will recognize that chair appointments at major academic medical centers typically follow national searches and involve candidates with substantial records in scholarship, clinical leadership, and mentorship.

Duke's Department of Dermatology sits within the Duke University School of Medicine, an institution consistently ranked among the top medical schools in the United States for research. The department's clinical footprint includes general dermatology, dermatologic surgery, and subspecialty care, alongside residency and fellowship training programs that feed the specialty's academic pipeline.

Leadership transitions of this kind also matter for the broader specialty. Academic chairs influence national conversations on disease classification, treatment guidelines, and training standards. They testify on reimbursement and access issues, contribute to the professional societies that set practice norms, and train the next generation of dermatologists who will manage conditions ranging from plaque psoriasis and atopic dermatitis to melanoma and cutaneous lymphoma.

The appointment comes at a moment when academic dermatology faces converging pressures. Departments nationwide are balancing expanding biologic and small-molecule therapeutic pipelines against workforce shortages, rising care demand, and the growing integration of telehealth and artificial intelligence into practice. A new chair inherits both the opportunities and the constraints of that environment.

Derm Field will follow the story as additional details emerge about Jacobe's start date, her vision for the department, and any leadership changes that accompany the transition. Her arrival at Duke positions the department for its next chapter in patient care, discovery, and training.